Newly Diagnosed Glioblastoma clinical trials

Explore recruiting newly diagnosed glioblastoma clinical trials.

Recruiting newly diagnosed glioblastoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Newly Diagnosed Glioblastoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicenter randomized double-blinded controlled phase 2 study evaluating the efficacy of valganciclovir as add-on therapy in glioblastoma patients

Sweden, Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus standard temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma.

Germany, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Adjuvant dendritic-cell immunotherapy plus temozolomide following surgery and chemoradiation in patients with newly diagnosed glioblastoma

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant with Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58)

Czechia, Italy, Germany, Spain, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, double-blind, placebo-controlled, randomized, proof-of-concept study evaluating LSTA1 when added to standard of care (temozolomide) versus temozolomide and matching LSTA1 placebo in subjects with newly diagnosed Glioblastoma Multiforme (GBM)

Estonia, Latvia, Lithuania

Therapeutic exploratory (Phase II) EU CTIS Study details

Newly Diagnosed Glioblastoma trials by city

Newly Diagnosed Glioblastoma in Toronto Newly Diagnosed Glioblastoma in Vancouver Newly Diagnosed Glioblastoma in Montreal Newly Diagnosed Glioblastoma in Calgary Newly Diagnosed Glioblastoma in Edmonton Newly Diagnosed Glioblastoma in Ottawa Newly Diagnosed Glioblastoma in Winnipeg Newly Diagnosed Glioblastoma in Quebec City Newly Diagnosed Glioblastoma in Hamilton Newly Diagnosed Glioblastoma in Kitchener Newly Diagnosed Glioblastoma in London Newly Diagnosed Glioblastoma in Halifax Newly Diagnosed Glioblastoma in New York Newly Diagnosed Glioblastoma in Los Angeles Newly Diagnosed Glioblastoma in Chicago Newly Diagnosed Glioblastoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease